Effect of different sustained polymers to control the drug release of ofloxain in matrix tablets

Vasanth Kumar Kunithala, Sushma reddy patlolla, Sateesh Kumar Vemula, Garrepally prasad, Vijay Kumar Bontha

Abstract


The present study is aimed to control the drug release, of slightly water soluble drugs like Ofloxain. It is a slightly soluble, highly permeable drug and the rate of its oral absorption is often controlled by the dissolution rate in the gastrointestinal tract. In this study an attempt was made to sustain the in vitro dissolution profiles of Ofloxain by using various sustained release polymers like carboxyl ethyl cellulose, HPMC K100, eudragitS100, sodium alginate, chitosan etc. Drug- Polymer Interaction Studies like FTIR, DSC were performed and results showed that there were no possible interactions between the drug and our entire tablet polymer. In conclusion, results suggest satisfactory result is obtained by F6.F7, F8 formulations so this type of polymers aresuitable for prepare Ofloxain sustained release tablets than more drug release is controlled by eudragit S100 from all the sustained polymers, because compare with acidic medium the Ofloxain solubility is less in base medium so eudragitS100 could potentially lead to retained the drug release in of oral Ofloxain products in acidic medium.

Keywords


Sustained release polymers, matrix formation, antibiotics. reduce dose frequency, reduce the side effects.

Full Text:

PDF

References


[1]. Abazinge M, Jackson T, Yang Q. (2000), “Comparison of In-vitro and In-vivo Release Characteristics of Sustained Release Ofloxain,” Drug Delivery, Vol.7 (2), 77-81

[2]. Published by the Indian Pharmacopoeia Commission, “Ofloxain drug,” Indian pharmacopeia,(2007); Vol.1, 156, 358. Vol-3,1468-1470.

[3]. M.Shahar yar, A.Ahamed Siddiqui, (2006) “Design of targeted dosage form of Ofloxain,” J.Serb.Chem.Sci, Vol.71 (12), 1269-1273

[4]. Meyer M, C. “Bioavailability of drugs and bioequivalence In: Encyclopedia of Pharmaceutical Technology” Marcel Dekker Inc, New york.; (1998); 2, 33-58.

[5]. Drew RH, Gallis HA. Ofloxain: its pharmacology, pharmacokinetics, and potential for clinical application. Pharmacotherapy. 1988;8(1):35–46.

[6]. Farinotti R, Trouvin JH, Bocquet V, Vermerie N, Carbon C. Pharmacokinetics of Ofloxain after single and multiple intravenous infusions in healthy subjects. Antimicrob Agents Chemother.1988 Oct;32(10):1590–1592.

[7]. Flor S. Pharmacokinetics of Ofloxain. An overview. Am J Med. 1989 Dec 29;87(6C):24S–30S

[8]. Lode H, Höffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. Pharmacokinetics of Ofloxain after parenteral and oral administration. Antimicrob Agents Chemother. 1987 Sep;31(9):1338–1342

[9]. Lode H, Höffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P. Comparative pharmacokinetics of new quinolones. Drugs. 1987;34 (Suppl 1):21–25

[10]. Wise R, Griggs D, Andrews JM. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S83–S89.

[11]. Verho M, Malerczyk V, Rosenkranz B, Grotsch H. Absence of interaction between Ofloxain and phenprocoumon. Curr Med Res Opin 1987;10:474–9.

[12]. Neuvonen PJ, Kivisto KT. Milk and yoghurt do not impair the absorption of Ofloxain. Br J Clin Pharmacol 1992; 33:346–8.

[13]. Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of Ofloxain. Eur J Clin Pharmacol 1991;41:569–71

[14]. Threlkeld DS, ed. Systemic Anti-Infectives, Fluoroquinolones. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, Feb 1994, 34

[15]. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870–6

[16]. .Jüngst G, Mohr R. Side effects of Ofloxain in clinical trials and in postmarketing surveillance. Drugs 1987; 34 (Suppl 1): 144-9.

[17]. Blum A. Ofloxain-induced acute severe hepatitis. South Med J 1991; 84: 1158.

[18]. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH; DILIN Research Group. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011 Jun; 9(6): 517-523.

Moseley RH. Antibacterial and Antifungal Agents; Quinolones. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd Edition. New York: Informa Healthcare USA, Inc, 2007. p. 532-3.


Refbacks

  • There are currently no refbacks.




Copyright (c)

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

Copyright@arjournals.org (Design) 2009-2021

 

Follow @arjournals on Twitter